• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

B cells and TLSs facilitate a response to ICI.

作者信息

Romero Diana

机构信息

Nature Reviews Clinical Oncology, .

出版信息

Nat Rev Clin Oncol. 2020 Apr;17(4):195. doi: 10.1038/s41571-020-0338-6.

DOI:10.1038/s41571-020-0338-6
PMID:32024979
Abstract
摘要

相似文献

1
B cells and TLSs facilitate a response to ICI.B细胞和三级淋巴结构促进对免疫检查点抑制剂的反应。
Nat Rev Clin Oncol. 2020 Apr;17(4):195. doi: 10.1038/s41571-020-0338-6.
2
Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response.在新辅助西普单抗治疗期间，具有皮肤边缘区淋巴瘤重叠组织病理学特征的三级淋巴结构与抗肿瘤反应相关。
J Cutan Pathol. 2021 May;48(5):674-679. doi: 10.1111/cup.13953. Epub 2021 Jan 13.
3
CD20CD22ADAM28 B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response.三级淋巴结构中的 CD20CD22ADAM28B 细胞促进免疫治疗反应。
Front Immunol. 2022 May 11;13:865596. doi: 10.3389/fimmu.2022.865596. eCollection 2022.
4
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.三级淋巴结构可改善黑色素瘤的免疫治疗和生存率。
Nature. 2020 Jan;577(7791):561-565. doi: 10.1038/s41586-019-1914-8. Epub 2020 Jan 15.
5
Biomimetic Tertiary Lymphoid Structures with Microporous Annealed Particle Scaffolds for Cancer Postoperative Therapy.仿生三级淋巴结构用微孔退火颗粒支架用于癌症术后治疗。
ACS Nano. 2024 Mar 26;18(12):9176-9186. doi: 10.1021/acsnano.4c01180. Epub 2024 Mar 18.
6
B cells! Don't go the wrong way in this tumor.B 细胞！在这个肿瘤里别走错路。
Immunity. 2024 Jul 9;57(7):1454-1456. doi: 10.1016/j.immuni.2024.06.007.
7
Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies.癌症中的三级淋巴结构：在抗肿瘤免疫中的双刃剑作用及潜在的治疗诱导策略
Front Immunol. 2021 Jul 29;12:689270. doi: 10.3389/fimmu.2021.689270. eCollection 2021.
8
Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.肿瘤内三级淋巴结构与肝细胞癌早期复发风险低相关。
J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.
9
New predictors for immunotherapy responses sharpen our view of the tumour microenvironment.新的免疫治疗反应预测因子使我们更深入地了解肿瘤微环境。
Nature. 2020 Jan;577(7791):474-476. doi: 10.1038/d41586-019-03943-0.
10
B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer.三级淋巴结构中的B细胞与胃癌的良好预后相关。
J Surg Res. 2017 Jul;215:74-82. doi: 10.1016/j.jss.2017.03.033. Epub 2017 Apr 1.

引用本文的文献

1
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.三级淋巴结构和免疫检查点阻断的多种机制及应用
J Exp Clin Cancer Res. 2025 Mar 5;44(1):84. doi: 10.1186/s13046-025-03318-6.
2
B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma.B 细胞 c-Maf 信号促进胰腺癌和黑色素瘤动物模型中的肿瘤进展。
J Immunother Cancer. 2024 Nov 27;12(11):e009861. doi: 10.1136/jitc-2024-009861.
3
The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer.
三级淋巴结构对非小细胞肺癌肿瘤预后和免疫微环境的影响。
Sci Rep. 2024 Jul 15;14(1):16246. doi: 10.1038/s41598-024-64980-y.
4
Heterogeneity of tertiary lymphoid structures in cancer.癌症中的三级淋巴结构异质性。
Front Immunol. 2023 Dec 4;14:1286850. doi: 10.3389/fimmu.2023.1286850. eCollection 2023.
5
Significance of CD103 tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer.CD103 组织驻留记忆 T 细胞对预测食管癌免疫检查点抑制剂疗效的意义。
BMC Cancer. 2023 Oct 20;23(1):1011. doi: 10.1186/s12885-023-11438-5.
6
Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions.精心设计智能疗法以实现小细胞肺癌的最佳治疗效果：最新进展与未来方向。
J Transl Med. 2023 Jul 14;21(1):468. doi: 10.1186/s12967-023-04338-6.
7
Deciphering the tumour immune microenvironment cell by cell.逐个细胞地解析肿瘤免疫微环境
Immunooncol Technol. 2023 Apr 7;18:100383. doi: 10.1016/j.iotech.2023.100383. eCollection 2023 Jun.
8
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.卡瑞利珠单抗联合阿帕替尼和艾瑞布林治疗多线治疗后晚期三阴性乳腺癌的多中心 II 期临床研究。
Nat Commun. 2022 May 31;13(1):3011. doi: 10.1038/s41467-022-30569-0.
9
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.将基于血液的PD-L1表达评估作为抗PD-(L)1免疫疗法生物标志物的挑战与不断演变的形势
Biomedicines. 2022 May 20;10(5):1181. doi: 10.3390/biomedicines10051181.
10
IgD ligation allows peritoneal cavity B cell proliferation.IgD 交联可导致腹腔 B 细胞增殖。
Immunobiology. 2022 Mar;227(2):152181. doi: 10.1016/j.imbio.2022.152181. Epub 2022 Jan 20.